CAR-T–and a side order of IgG, to go?–Immunoglobulin replacement in patients receiving CAR-T cell therapy

JA Hill, S Giralt, TR Torgerson, HM Lazarus - Blood reviews, 2019 - Elsevier
The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in …
被引用次数：134 相关文章

[引用][C] CAR-T–and a side order of IgG, to go?–Immunoglobulin replacement in patients receiving CAR-T cell therapy

JA Hill, S Giralt, TR Torgerson, HM Lazarus - Blood Reviews, 2019 - cir.nii.ac.jp
CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving
CAR-T cell therapy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文 …
[HTML] nih.gov

[HTML][HTML] CAR-T–and a side order of IgG, to go?–Immunoglobulin Replacement in Patients Receiving CAR-T Cell Therapy

JA Hill, S Giralt, TR Torgerson, HM Lazarus - Blood reviews, 2019 - ncbi.nlm.nih.gov
The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in …

CAR-T-and a side order of IgG, to go?-Immunoglobulin replacement in patients receiving CAR-T cell therapy

JA Hill, S Giralt, TR Torgerson… - Blood …, 2019 - pubmed.ncbi.nlm.nih.gov
The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in …

CAR-T-and a side order of IgG, to go?-Immunoglobulin replacement in patients receiving CAR-T cell therapy.

JA Hill, S Giralt, TR Torgerson, HM Lazarus - Blood Reviews, 2019 - europepmc.org
The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in …